Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Halo is doing a lot of business with Roche!!!! If and when new deals are announced the stock should fly.
Probably not. You can’t blame someone for cashing in stock. It’s not like he’s selling into major strength. He’s not timing this just selling to pick up some cash. Maybe he wants a vacation home. I never look at program insider selling as a major negative. There hasn’t been any insider buying in a long time which concerns me a little bit but the buybacks can be looked at as an indirect way of insider buying I guess.
On another note I think that it takes at least a couple years to integrate an acquisition so we’ll see if it was money well spent soon enough. Certainly looks like it’s been accretive so far not that much.
I’m not a big fan of companies that over hype their stock with BS announcements so lack of announcements doesn’t bother me as much as it does others in this thread. There seems to be a lot of positive stuff going on just not a lot of PR. That being said if you call the company they should call back. No response is not acceptable.
Labarre should have plenty of money to pay tax on a few shares from the 20k per month he’s been selling. I think it’s a non event but fun to talk about anyway.
Saw this in the morning when stock was up close to 2 bucks. Was kind of surprised it fizzled out. Oh well.
Sorry for the confusion. I’m speaking in general terms about injectors. Not specific to this deal. Getting SC delivery to market quicker will make it very tough for competition against Enhanze. That extra year or two makes a huge difference.
Great find!!!! This should save and make Partners a lot of money. Maybe this makes doing business with Halo vs any would be competitor a no brainer. Maybe Helen knows what she’s doing after all.
Also until recently I really never paid much attention to the injector market. She is definitely on to something.
I guess the question is are they developing themselves?
https://finance.yahoo.com/news/viridian-therapeutics-enters-autoinjector-pen-120000066.html
Wonder who they are working with?
Interesting fyi on ABOS. RA capital owns 25 percent of the shares. These guys are pretty good investors. Not a bad strategy to go thru their 13f filings and see what they hold. I said on a previous post that a good strategy is to buy companies stock that do business with Halo early in their process. This looks like a good bet if you like early stage biotech. Can still fail. If I was 20 years younger I would probably buy it. I own a few RA funds so i probably have some shares indirectly.
Frank Thomas is a hall of fame baseball player for the white Sox. Look for his Nugenix testosterone commercials. Halo has 300 million of commercial revenues. Hylenex is maybe 25 million of that.
Few hundred million in revenue can get you there. Growth looks good. If they hire Frank Thomas I say they get there.
Just that. Doesn’t fit.
Thanks for the explanation. Coincides with approvals and the end of the pancreatic cancer trials and transformation of the company. Lots of people on this board forget what happened and how quickly the Company transitioned out of that debacle. Rising rates have had a negative effect on the biotech market in general clearly because of discounted future cash flow. As rate sentiment has changed the stock has moved up with the index. I expect the chart to continue positively for years to come. Shares used to convert debt to stock will be higher than the buyback price and will show a positive result and a higher return than anything else the company could have done. Additionally it provided capital for ATRS acquisition which will be positive, especially when they sell the commercial division for real dollars.
I’ll try and answer the best I can.
Enhanze is ten years ahead of the competition. Won’t be hard to spend cash flow to slow it down for many more years.
Owning the stock for as long as I have gives me enough knowledge to assess current management and known how long it takes to get to market and what the obstacles are. Haven’t missed a call in 17 years. Helen knows what she is doing and I have confidence in her ability. If you don’t that’s your opinion and maybe you’re right and I’m wrong.
The debt is convertible and has virtually no interest. Buying back cheap shares to retire it is a good strategy.
I think the strategy is to build up commercial business and sell it. She has to play it out and when the opportunity comes she’ll take it. She wanted AI and had to buy commercial business to get it. That will raise a lot of cash to put elsewhere.
I don’t agree that buybacks are manipulation they make sense when stock is undervalued by the market.
It also makes sense that stock gets taken down on small volume. I’m not a trader but it usually gets far lower than it should and recovers eventually. Revenues and profits are pretty easy to predict on a quarterly basis. Also index funds might play a part in volatility. But if the company can take advantage of cheap then I say buy them. Not manipulation just smart business.
That’s all I got. Just an investor not a biology major but know how the industry rolls.
How about the possibility that ARGX is testing the AI. We still haven't heard from Halo on that. i'm sensing that over the last couple years these companies are keeping cards closer to the vest than they were before. Just a feeling and have no evidence to back it up. I will say that until last year Helen never promised any deal that she didn't deliver. i think that she delivered 2/3 deals but ARGX will not let that be announced for some reason.
They will sign many new deals in my opinion. One really important thing I’ve learned is that money makes more money. When you look at what’s going on in this niche Halo has so much more money and cash flow then any other company there is really no way, short of total stupidity and absolute incompetency that Halo won’t be able to trounce the competition. Take a good look at this last quarter and the projections for 2024 and tell me how a startup is going to have any impact on Halo. It takes so long to get approvals and dilutive capital raises and bumpy results along the way that Halo will be way larger or sold for a big number by the time they collect their first dime. I bought halo 17 years ago and here we are today finally a cash flow machine with a very solid management team that’s built billions of value and will continue to do so.
I attribute the poor stock performance to the fact that Halo is heavily owned by index funds and institutional buyers that reduce the public float. It’s easy for hedge funds to manipulate the stock in a quiet period, bring down the price and know they will make money at earnings time when the stock goes up.
I also feel that Halo is in an unusual position with their clients that they can’t make announcements without permission. A few months of secrecy may make a huge difference in very competitive situations and Halo clearly is not at liberty to talk. I can’t think of Halo announcing anything regarding a client that wasn’t done in conjunction with the client.
All that being said it takes money to make money and we are making lots of it for years to come. I disagree that Helen needs to be replaced, she has made very good decisions and runs a very low overhead very profitable easily scalable business. I’ve always thought she was going to sell the commercial Antares business and still think that. It’s becoming more valuable and may bring 1 billion some day and the AI business will have been purchased for free.
To sum it up:
Great cash flow
No real competition in the foreseeable future
A growing market with a scalable low overhead model
Solid management
Solid balance sheet
Many more deals to come just have to wait for clients to want to announce which makes it difficult to get news. Have to do research on your own and most of us are too lazy.
And a very low stock price. I think it’s worth what Bio thinks it is. It will get there and more but it will take time. I’ll never sell this one because I love cash flow. My share of net GAAP income equals what I originally invested every year. That’s a 100 percent return every year. Just doesn’t show up in the stock price yet but it will. I’m very optimistic. This is going to be a breakout year.
Take a look at royalty pharma. They acquire royalty streams all of the time. The stock is 50 percent off the highs. Making acquisitions doesn’t always work that well in biotech, just look at Abbvie and the billions wasted. Antares is looking pretty good so far and the deal makes sense and should yield a good return. If something attractive comes along Halo will find the money easily to make the deal. Stock buybacks are a solid tax free way to return money to shareholders. Will yield much more than a money market. Halozyme didn’t get to this point by accident. There is a lot going on here for the foreseeable future with in place deals. Things will get a lot better in my opinion and very soon.
the most important part of Buy Backs is that its a tax free way to give money back to the shareholders. They can keep buying back as far as I'm concerned. The best part of the call were the phenomenal cash flow and EBITDA numbers. They are quietly building up this Company and it is showing up in the numbers. It's going to be very hard for any other Company to compete with them in this space.
I’ll agree that they don’t keep their website current. Definitely need to do that. We’ll see tomorrow what’s been going on.
Xers is Halo in 2006. If you got 18 years I think you should buy it. I’ll take the cash flow over the future dilution and continued losses. Either Amgen going to buy Xers for their own drugs in the future or maybe they’re only interested in keeping Xers product off the market. Time will tell but it will be a long time.
Halo can’t announce anything without partners permission. This will always be an issue so need to get used to digging for info. on your own because these big Pharma Companies don’t want competition to know what they’re doing until they have to.
Generally speaking the price is down because of argx recent phase 3 failure potential competition and lack of news. Very easy to manipulate for traders because of low float. This happens every now and then but fundamentals are excellent. That’s why I don’t trade stocks because sometimes things just don’t make sense. This stock will go much higher when rates start coming down. This is a mature company and will trade on future cash flow moving forward. Not on speculation like Xers.
Just a guess but this is one of those deals that never was announced. AI would be halozyme in all probability. Keep in mind that halozyme has no control over their news releases because client don’t want competition to know.
Xeris Biopharma (Xers). Reminds me of when Halo did first deal with Roche (2006). Finally approved 2012ish. (Herceptin). At 2006 Enhanze was already approved. That took 5 or so years prior. What I’m saying is this is going to take Xers a long time and maybe I can see a Company like Amgen buying it for themselves and using for their own because the market cap is a rounding error. Halo has the goods and is way ahead in the game by close to a decade. I believe that we will see deals and higher prices. Maybe more on the non exclusive side of things cause it’s cheaper to buy. I can’t explain why the price is down so much but I can see a reason for it to go up from here.
Maybe they need a break from all these road shows. I think investors are aware that the company exists by now and the road shows are pretty much a time waster. Talk to me about Xers in about 5 years because that’s what it will take to find out if they even have something. Like it when stock goes up a little per day on a consistent basis. Usually is a good sign. Would like to see some movement on AI business but it will take a couple years to gain traction. Will see what happens but solid cash flow is way better than negative cash flow. Halo can buy Xers with their checking account balance. Not worried about them.
That’s why Helen should not discuss pending deals because it sets expectations that sometime don’t get achieved. But I guess she would get blamed for that too. When your clients want you to be tight lipped that’s all you can do so I don’t think they’re ever going to be in a position to comment on things the way most people want. All that I worry about is free cash and it seems to be plentiful for a long time. This was a very good presentation. The analysts should follow something else because they are always clueless.
I guess that means people don’t like cash flow anymore. Is that correct? Cash flow creates the ability to take advantage of opportunities in the future. People want above average returns so tell me why they wouldn’t buy and hold this stock.
I’ve been in Halo for at least 17 years.
There have times when the stock has done nothing or gone down over that period but I’ve made 11 times my investment over that period. I’ll just say that I love companies that generate cash on a yearly basis that equals what I invested. One day the market will wake up and see the huge value that we have here. Keep in mind that halo provides a product to Companies that keep their cards close to the vest and don’t want halo advertising what their doing. I’m sure putting this much info out this morning took a lot effort and couldn’t happen without cooperation from their clients. The open this morning was pure manipulation and was easy money for anyone who listened to the conference and is a trader. This is a cash machine for a long time to come so quit worrying about short term price movement. Very little float makes this very easy to play with. Helen and crew worked very hard putting this together and did a great job. This was worked on for a long time tying together a lot of moving parts. Just try and understand that partners need to keep things quiet cause billions are at stake. That’s why you don’t get as much info. As you would like.
You’re probably right. I always thought they would sell off the Antares commercial business, and still think it will happen. Now that rates are dropping we’ll see more action on the upside once the argx and Roche deals clear up. Argx tried for a grand slam and will end up hitting 345 with 40 homers and 100+ rbis. Still really good. Next six months should be interesting. I’m hoping positive because I like Helen. She’s done a great job so far but we need her plan to work and we’ve yet to see it.
Story telling doesn’t work for long. You need results. Halo has had very positive results, they have many large brokers following their stock. Let’s see what happens in the next six months and if this Antares deal actually pays off. If we see worse results and no Antares deals get booked I’ll also be asking for a change at top
What do you think should be done that management hasn’t been doing? I need a reason to change other than a couple deals that are either delayed or scrapped. From what I can see the lower price reflects Argx failures and Roche delays neither of which is Halos fault.
This was the best quarterly report I’ve seen since I bought the stock at 3 and the market cap was 50 million. Helen is without question the best CEO that the company has had and she’s built enormous value. She inherited PEG Ph 20 and was in a position where she didn’t have much of a choice but to play it out. When it failed she was prepared and moved immediately to focus on Enhanze and did what it took to move forward. Halozyme now generates huge cash flow has raised money at virtually zero interest rates and very high conversion numbers and has a commercial business that could probably be sold at the whole price that she paid for Antares. Stock price has performed pretty much along with Biotech in general which has been weak to say the least. When interest rates bottom out and drug pricing settles down the stock will move back up and so will Biotech. Stock buybacks will really pay off in the long run. Keep in mind that that is the most tax efficient way to get money to shareholders. It’s hard to find fault with what she’s done. The stock price will eventually reflect this.
This was the best quarterly report I’ve seen since I bought the stock at 3 and the market cap was 50 million. Helen is without question the best CEO that the company has had and she’s built enormous value. She inherited PEG Ph 20 and was in a position where she didn’t have much of a choice but to play it out. When it failed she was prepared and moved immediately to focus on Enhanze and did what it took to move forward. Halozyme now generates huge cash flow has raised money at virtually zero interest rates and very high conversion numbers and has a commercial business that could probably be sold at the whole price that she paid for Antares. Stock price has performed pretty much along with Biotech in general which has been weak to say the least. When interest rates bottom out and drug pricing settles down the stock will move back up and so will Biotech. Stock buybacks will really pay off in the long run. Keep in mind that that is the most tax efficient way to get money to shareholders. It’s hard to find fault with what she’s done. The stock price will eventually reflect this.
Keep in mind that public float is virtually nil so directionally the stock can overshoot. RA capital runs a biotech fund. They are very good at what they do and have recently called capital commitments. They must feel we are nearing a bottom in biotech.
Keep in mind that public float is virtually nil so directionally the stock can overshoot. RA capital runs a biotech fund. They are very good at what they do and have recently called capital commitments. They must feel we are nearing a bottom in biotech.
Deals take time to document. I’ve never seen where Helen hasn’t delivered on promised deals. Not worried but I guess you never know. Biotech is dead money for now but recently I received a capital call on RA accounts. They must thinks things are getting cheap out there.
All news is positive. The xbi is down 30% from the highs in the last year. Halozyme is just performing along with a weak sector. Halo collects royalties and interest rate are way up. This affects the present value of future cash flows. I expect the stock to be dead money for a while but once rates start dropping it will start moving up. I’m guessing a big chuck of institutional ownership is index related so that moves the price lower when people are selling. Company is fundamentally solid and stock will eventually take off. Might be a while before that happens.
The stock was like 60 when they announced the Halozyme deal. Now it’s 400 plus. Should have bought that one. Next time halozyme makes a deal with a small company I’m buying the stock.
The debt Carry’s a coupon of under 1 percent and an adjusted conversion price in the 70s per share. I would say that was a very good deal at the time a looks way better these days. Nothing has changed with the company since the high 50s so I think we’ll see it soon enough again. The argx deal will be a catalyst to move the stock much higher. They are getting huge press and vvgart looks like a major winner.